Putative neuroprotective effects of caffeine in clinical trials. Concluding remarks.
de Mendonça
Alexandre
A
Institute of Molecular Medicine and Faculty of Medicine, University of Lisbon, Portugal.
Cunha
Rodrigo A
RA
D000544:Alzheimer Disease / Q000188:drug therapy*; D002110:Caffeine / Q000627:therapeutic use*; D002986:Clinical Trials as Topic / Q000379:methods*; D006801:Humans; D018696:Neuroprotective Agents / Q000627:therapeutic use*
D018696:Neuroprotective Agents; D002110:Caffeine